siRNA Sector Heats Up With IPOs, Acquisitions and Billion-Dollar Licences

The RNAi field is experiencing a sharp capital and dealmaking surge. City Therapeutics raised about USD 230 million in an IPO after a USD 135 million Series A in 2024 and a USD 99.5 million Series B in 2026, with pipeline assets including CITY-FXI, a Factor XI RNAi programme in Phase I, and CITY-RBP4, a potential first-in-class RBP4-targeting therapy for Stargardt disease.

On 19 October, Merck KGaA agreed to acquire Silence Therapeutics for about USD 1.3 billion, while ADARx Pharmaceuticals raised more than USD 500 million via IPO on 1 October and Souffle Therapeutics closed a USD 135 million Series B on 13 October, showing that next-generation delivery, stabilisation and extrahepatic targeting have reopened investor appetite for nucleic-acid medicines.

Daily News
Abbott Pays USD 40mn Upfront for Disco AND-Gated Bispecific Option
2026-11-20
MegaRobo Raises USD 200mn to Scale Physical-World AI Infrastructure
2026-11-20
Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform Deal
2026-11-19
Pfizer Licenses Starna's In Vivo CAR-T Platform for Up to USD 2.63bn
2026-11-19
Zelgen's CD3×DLL3 Trispecific Hits Pivotal Endpoint in Relapsed SCLC
2026-11-19
Latest Report
AI- in-BD- Portfolio
Details